272773-11-2 Usage
Uses
Used in Pharmaceutical Industry:
3-Bromo-5-isoxazolecarboxylic acidmethylester is used as a key building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique chemical structure allows for the creation of a wide range of medicinal compounds with diverse therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromo-5-isoxazolecarboxylic acidmethylester is utilized as an intermediate in the synthesis of herbicides and plant growth regulators. Its incorporation into these products helps enhance their effectiveness in controlling weeds and promoting plant growth, thereby improving agricultural productivity.
Used in Chemical Research:
3-Bromo-5-isoxazolecarboxylic acidmethylester is employed as a valuable intermediate in chemical research, enabling the exploration of new chemical reactions and the synthesis of novel organic compounds. Its versatility and reactivity make it a useful tool for advancing scientific understanding and developing innovative applications in the chemical domain.
Check Digit Verification of cas no
The CAS Registry Mumber 272773-11-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,7,2,7,7 and 3 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 272773-11:
(8*2)+(7*7)+(6*2)+(5*7)+(4*7)+(3*3)+(2*1)+(1*1)=152
152 % 10 = 2
So 272773-11-2 is a valid CAS Registry Number.
InChI:InChI=1/C5H4BrNO3/c1-9-5(8)3-2-4(6)7-10-3/h2H,1H3
272773-11-2Relevant academic research and scientific papers
Jin, Shuyu,Sun, Xiuyun,Liu, Dan,Xie, Hua,Rao, Yu
, p. 1333 - 1345 (2019)
The discovery and development of a novel HER-2 tyrosine kinase inhibitor for the treatment of HER2-positive breast cancer are presented in this article. EGFR family has been recognized as a crucial meditator in the cancer progression; HER-2 tyrosine kinase was one of the members among them. In the effort to explore potent HER-2 inhibitors, a novel series of 4-anilino-3-cyanoquinoline derivatives have been designed, synthesized and evaluated. Most compounds possessed modest proliferation inhibition on SK-BR-3 cell line and HER-2 kinase. Compound 16 appeared to be the most potent compound (HER-2 kinase IC50: 19.4?nM, SK-BR-3 IC50: 94?nM). In the experiment of cellular cytotoxicity assay, compound 16 shows a much lower cytotoxicity than neratinib on Beas-2b cell line (Human bronchial epithelial cells). In conclusion, compound 16 would be a promising lead compound for further anti-breast cancer drug discovery.
